Drug Profile


Alternative Names: Chimeric Antibody (TRC105) to CD105; DE 122; NSC#754227; TRC-105

Latest Information Update: 18 Jul 2017

Price : $50

At a glance

  • Originator Roswell Park Cancer Institute
  • Developer National Cancer Institute (USA); Santen Pharmaceutical; TRACON Pharmaceuticals; University of Alabama at Birmingham; University of Minnesota
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ENG protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemangiosarcoma
  • Phase II Choriocarcinoma; Glioblastoma; Hepatocellular carcinoma; Renal cell carcinoma; Soft tissue sarcoma; Wet age-related macular degeneration
  • Phase I/II Breast cancer
  • Phase I Non-small cell lung cancer
  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Colorectal cancer
  • Discontinued Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer

Most Recent Events

  • 05 Jul 2017 Phase-II clinical trials in Wet age-related macular degeneration (Combination therapy) in Philippines (Intravitreous) (NCT03211234)
  • 13 Jun 2017 Bristol-Myers Squibb in collaboration with Tracon Pharmaceuticals plans a phase I trial for Non small cell lung cancer (Combination therapy, Metastatic disease) in USA (NCT03181308)
  • 05 Jun 2017 Pharmacodynamics data from the phase Ib/II TRAXAR trial in Renal cell carcinoma and the phase Ib/II trial in Soft Tissue Sarcoma released by TRACON Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top